Afya (NASDAQ:AFYA) Sees Unusually-High Trading Volume on Analyst Upgrade

Key Points

• JPMorgan upgraded Afya from Neutral to Overweight, while lowering its price target from $21 to $19. The upgrade triggered unusually high trading volume, with shares recently trading near $13.86.
• Analyst sentiment remains cautious overall: Afya has a consensus rating of Hold and a consensus price target of $17.25, despite additional upgrades from Bradesco Corretora, Zacks Research, and Wall Street Zen.
• Afya reported quarterly EPS of $0.43, exceeding the $0.40 consensus estimate, but an insider sold 4,161 shares for approximately $55,341. Institutional investors own about 88% of the company.

Afya Limited (NASDAQ:AFYA - Get Free Report) saw unusually-high trading volume on Wednesday after JPMorgan Chase & Co. upgraded the stock from a neutral rating to an overweight rating. JPMorgan Chase & Co. now has a $19.00 price target on the stock, down from their previous price target of $21.00. Approximately 152,529 shares were traded during mid-day trading, an increase of 2% from the previous session's volume of 149,674 shares. The stock last traded at $13.8610 and had previously closed at $13.91.

Other research analysts have also issued research reports about the stock. Weiss Ratings lowered shares of Afya from a "hold (c)" rating to a "hold (c-)" rating in a research note on Friday, July 31st. Bradesco Corretora upgraded shares of Afya to an "outperform" rating and set a $17.00 price target on the stock in a report on Thursday, September 24th. Bank of America reaffirmed a "neutral" rating on shares of Afya in a research note on Thursday, June 11th. Zacks Research upgraded Afya from a "strong sell" rating to a "hold" rating in a report on Monday. Finally, Wall Street Zen raised Afya from a "hold" rating to a "buy" rating in a research report on Saturday, September 5th. Two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Afya has a consensus rating of "Hold" and a consensus price target of $17.25.

Insider Buying and Selling at Afya

In related news, insider Santos Welder Ferreira sold 4,161 shares of the company's stock in a transaction on Monday, October 5th. The shares were sold at an average price of $13.30, for a total transaction of $55,341.30. Following the completion of the sale, the insider directly owned 35,000 shares of the company's stock, valued at approximately $465,500. This represents a 10.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Key Stories Impacting Afya

Here are the key news stories impacting Afya this week:

• Positive Sentiment: JPMorgan upgraded Afya (AFYA) from “Neutral” to “Overweight,” citing a more favorable outlook and setting a $19 price target. Although the target was lowered from $21, it still implies substantial potential appreciation from recent trading levels. JPMorgan upgrades Afya to Overweight
• Positive Sentiment: Zacks Research raised Afya’s rating from “Strong Sell” to “Hold.” While not a bullish recommendation, the change removes a notably negative rating overhang and may support investor confidence.
• Positive Sentiment: Afya shares recently gained 4.5% to $13.91, with the company’s low valuation potentially attracting value-oriented investors. The stock trades at approximately 8.5 times earnings, while its latest quarterly EPS of $0.43 exceeded the $0.40 consensus estimate.
• Neutral Sentiment: Despite JPMorgan’s upgrade, broader analyst sentiment remains cautious. Afya has an average rating of “Hold” and an average price target of $17.75, indicating upside but limited consensus conviction.
• Negative Sentiment: Insider Santos Welder Ferreira sold 4,161 shares for approximately $55,341, reducing his position by 10.63% to 35,000 shares. The transaction is relatively small but may be viewed as a modest negative signal by investors. Afya insider share sale

Institutional Investors Weigh In On Afya

Several hedge funds and other institutional investors have recently made changes to their positions in AFYA. Banco BTG Pactual S.A. bought a new stake in shares of Afya in the 4th quarter worth approximately $462,000. Engineers Gate Manager LP bought a new stake in shares of Afya during the second quarter valued at approximately $325,000. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Afya in the second quarter valued at $67,000. 88.02% of the stock is owned by institutional investors and hedge funds.

Afya Stock Down 0.4%

The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of 8.45, a price-to-earnings-growth ratio of 1.49 and a beta of 0.34. The business has a 50 day moving average of $13.78 and a 200 day moving average of $14.26. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.20 and a quick ratio of 2.20.

Afya (NASDAQ:AFYA - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.03. The firm had revenue of $187.80 million for the quarter, compared to analyst estimates of $189.62 million. Afya had a net margin of 20.55% and a return on equity of 17.58%. On average, equities analysts anticipate that Afya Limited will post 1.86 EPS for the current year.

Afya Company Profile

Afya Limited NASDAQ: AFYA is a Brazil-based medical education and health technology company. The company provides education and professional development for physicians and other healthcare professionals, with activities spanning undergraduate medical programs, medical residency preparation, specialization courses, continuing medical education and digital learning services.

Afya also develops technology-enabled products designed to support healthcare professionals throughout their careers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.